MR-35602

N/A

Report date: 2025/01/26 16:00:46
NME

Base Information

Drug NameMR-35602
Drug Alias Nametriple acetylcholinesterase inhibitor/5-HT4 receptor agonist/5-HT6 receptor antagonist (INSERM/Univ Caen Basse-Normandie/Univ Montpellier/CNRS/Univ Aix-Marseille)MR-35602
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 6 (5-HT6) receptor antagonistsSerotonin 4 (5-HT4) receptor agonistsAcetylcholinesterase inhibitors
TargetsSerotonin 4 (5-HT4) receptorSerotonin 6 (5-HT6) receptorAcetylcholinesterase
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInstitut National De La Sante Et De La Recherche Medicale
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Sante Et De La Recherche MedicaleUniversite de Caen Basse-NormandieUniversity of Montpellier +[5] 
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A